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Abstract: Since the 1950s, when serotonin (5-HT) was discovered in the mammalian central nervous system (CNS), an
enormous amount of experimental evidence has revealed the pivotal role of this biogenic amine in a number of cognitive
and behavioural functions. Although 5-HT is synthesized by a small group of neurons within the raphe nuclei of the brain
stem, almost all parts of the CNS receive serotonergic projections. Furthermore, the importance of 5-HT modulation and
the fine-tuning of its action is underlined by the large number of 5-HT binding sites found in the CNS. Hitherto, up to 15
different 5-HT receptors subtypes have been identified.
This review was undertaken to summarize the work that has explored the pathophysiological role of one of these
receptors, the 5-HT2C receptor, that has been emerged as a prominent central serotonin receptor subtype. The physiology,
pharmacology and anatomical distribution of the 5-HT2C receptors in the CNS will be firstly reviewed. Finally, their
potential involvement in the pathophysiology of depression, schizophrenia, Parkinson’s disease and drug abuse will be
also discussed.
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BASIC ANATOMY OF 5-HT SYSTEM
More than fifty years have passed since Twarog and Page
[1] isolated an indole, identified as serotonin (5-HT), in the
mammalian brain. Subsequently, Brodie and colleagues [2]
suggested that 5-HT might serve as a neurotransmitter in the
central nervous system (CNS). The result was one of the
most important discoveries in science, giving birth to a new
branch of neuroscience [3]. Serotonin is one of the oldest
biologically active compound on earth, found in a variety of
plants and animals. In vertebrates, the majority of the
neurons containing 5-HT are grouped in 9 nuclei named B1
to B9, located in the medial part of the brainstem, generically
called the raphe nuclei [4] (Fig. 1). These midline clusters
can be divided into two major groups. The caudal or inferior
group, localized in the medulla, contains the three nuclei
projecting essentially to the grey matter of the spinal cord:
the nucleus raphe magnus (NRM, cell group B5), nucleus
raphe obscurus (NRO, cell groups B1-B2-B3), and nucleus
raphe pallidus (NRP, cell group B4). The rostral or superior
group, situated in the pons/mesenchephalon, contains the
dorsal raphe nucleus (DRN, cell groups B6 and B7) and the
median raphe nucleus (MRN, cell group B8). These nuclei
supply about 80% of the serotonergic innervation of the
forebrain. Even if in many brain areas, the innervation
coming from the two nuclei overlaps, in certain regions the
innervation comes exclusively or prevalently from one
nucleus only. For example, the dorsal hippocampus receives
a serotonergic innervation only from MRN, other areas
innervated preferentially from this nucleus are: the medial
preoptic area, the suprachiasmatic nucleus, the olfactory bulb
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and the medial septum nucleus. The dorsal raphe nucleus
innervates the corpus striatum, the globus pallidus, the lateral
septum nucleus and the amygdala, and provides most of the
innervation of the prefrontal cortex. Serotonin-containing
cell bodies of the raphe send projections to both dopami-
nergic cells in the ventrategmental area (VTA) and subs-
tantia nigra (SN), and to their terminal fields [5-8]. A
comparison between the number of 5-HT terminals and the
total number of axon terminals in the VTA reveals that the
majority of these are serotonergic. Moreover, electron
microscopy demonstrates the presence of synaptic contacts
of [
3
H]5-HT labeled terminals with both dopaminergic and
non-dopaminergic dendrites in all subnuclei of the VTA and
the SN pars compacta and reticulata [5, 8, 9]. These 5-HT
axon terminals form many symmetric (inhibitory) contacts
with non-dopaminergic and non-accumbens projecting
neurons in the VTA, suggesting that 5-HT exerts an inhibi-
tory influence on certain non-DA VTA neurons [7]. The
DRN innervates, together with the MRN the ventral part of
the hippocampus, the nucleus accumbens and various nuclei
of the thalamus and the hippocampus [10-12]. Moreover,
extensive serotonergic connections between the DRN and the
MRN also exist [13].
5-HT RECEPTORS
The first evidence for the existence of multiple subtypes
of 5-HT receptors was provided by Gaddum and Picarelli
whuch discovered the so-called M and D receptors [14].
Definitive evidence for two distinct recognition sites was
reported by Peroutka and Snyder [15] who classified 5-HT in
two subtypes 5-HT1 or 5-HT2 depending on their affinity to
[
3
H]-5-HT and [
3
H]-spiperone, respectively. A vast amount
of research has led to the discovery and characterisation of a
plethora of 5-HT receptor subtypes. At present, seven classes
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of 5-HT receptors (5-HT1-7 receptors) have been identified
which comprise at least a total of 15 subtypes [16] (Table 1).
Not surprisingly, with so many potential targets, distributed
throughout all the CNS (Table 2), 5-HT is a major neuro-
transmitter involved in a such large number of physiological
and pathological processes. 5-HT receptors are cell surface
receptors that have been classified on the basis of their
pharmacological responses to specific ligands, sequence
similarities at the gene and amino acid levels, gene
organisation, and second messenger coupling pathways [16,
17]. Except for the 5-HT3 receptor, which is a ligand gated
channel, all 5-HT receptors belong to the seven
transmembrane domain G-protein-coupled receptor (GPCR)
superfamily [16, 18, 19]. The 5-HT3 receptors have three
intracellular loops, an extracellular N-terminus, and an
itrancellular C-terminus. Of the three intracellular loops, the
third (i3) loop is typically the longest. In the brain, high
densities of 5-HT3 receptors are found in the area postrema,
cerebral cortex and limbic regions such as the hippocampal
formation and the amygdala [20, 21]. The 5-HT1 receptor
class is comprised of five receptor subtypes (5-HT1A, 5-
HT1B, 5-HT1D, 5-HT1E and 5-HT1F), which, in humans, share
40–63% overall sequence identity and couple preferentially,
although not exclusively, to Gi/o to inhibit cAMP formation
(see Table 1). To date, a functional role in a variety of tissues
has only been demonstrated for the 5-HT1A, 5-HT1B and 5-
HT1D receptors. The 5-HT1C designation is now vacant, since
this receptor was reclassified as 5-HT2C due to structural,
operational and transductional similarities with the 5-HT2
receptor subclass [16]. Dense labeling of 5-HT1 receptor
binding sites is typically found in the hippocampus, septum,
some amygdaloid nuclei and the cortex including the frontal
and cingulate regions. Furthermore, high density of 5-HT1A
receptors are localised to the raphe nuclei where they have
been shown to act as somatodendritic autoreceptors
regulating the firing activity of 5-HT neurons [20]. The 5-
HT2 subfamily will be discussed in the further paragraph.
The 5-HT3 receptor is the oldest of the serotonin receptors, it
is a ligand-gated cation channel belonging to the nicotine/
GABA receptor superfamily with four putative transmem-
brane domains. It is a pentamer consisting of five monomers,
at least three different monomers (5-HT3A/3B/3C) have been
found in the brain [22, 23]. The 5-HT4, 5-HT6 and 5-HT7
receptors have all been demonstrated to be preferentially
coupled to Gs and promote cAMP formation. However, the
sequence dissimilarity justifies classification into different
groups. Although the functional significance remains to be
revealed, the interest in these receptor subtypes have
increased after the demonstration that several antipsychotic
drugs including clozapine, chloropramazine, risperidone and
olanzapine display a significant affinity for these sites [24].
Two subtypes of the 5-HT5 receptor (5-HT5A and 5-HT5B),
sharing 70% overall sequence identity, have been found in
rodents, whereas only the 5-HT5A subtype has been found in
humans [25, 26]. Recent studies have shown that the human
recombinant 5-HT5A receptor activation produced an
inhibition of cAMP production, indicating negative coupling
to cAMP via Gi and Go [27]; however, the receptor may also
couple positively to cAMP. The human 5-HT5B gene does
not encode a functional protein because its coding sequence
is interrupted by stop codons. The 5-HT5B receptor is the first
example of a brain-specific protein not found in human [28].
5-HT2 FAMILY
Among the multiple classes of 5-HT receptors described
in the central nervous system [16, 17, 29], much attention
has been devoted to the 5-HT2 receptor family since it has
been shown by experimental and clinical observation that it
Fig. (1). Midsaggital view of the rat brain with serotonin-immunoreactive cell bodies. The blue and red ovals encompass the two major
subdivisions of the brain serotonergic system. The major functions of 5-HT2C receptors, and the brain areas where they occur are also shown.
Abbreviations: DRN, dorsal raphe nucleus ; MRN, median raphe nucleus; NRM; nucleus raphe magnus; NRO, nucleus raphe obscurus. Cell
groups B1 to B9 according to the terminology of Dahlström and Fuxe (1964).
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may represent a possible therapeutic target for the
development of drugs for a range of CNS disorders such as
schizophrenia, depression, drug abuse, eating disorders,
Parkinson’s disease and epilepsy [30-33]. In fact, 5-HT2
receptors are major targets for a wide array of psychoactive
drugs, ranging from non-classical antipsychotic drugs,
anxiolytics and anti-depressants, which have a 5-HT2
antagonistic action, to hallucinogens, which are agonists of
the 5-HT2 receptors [34-37]. Furthermore, recently it has
been shown that 5-HT2 receptors have a potential signifi-
cance in brain development [38], and in experience-
dependent plasticity in the visual cortex [39]. The 5-HT2
receptor form a closely related subgroup of G-protein-
coupled receptors and show the typical heptahelical structure
of an integral membrane protein monomer. They are
currently classified as 5-HT2A, 5-HT2B and 5-HT2C subtypes
[16, 17, 21, 29], based on their close structural homology,
pharmacology and signal transduction pathways [16, 17, 21,
29] and they are differently localized in the brain (Table 3).
The amino acid sequence of the 5-HT2 receptors shares an
high degree (>70%) of identity within the transmembrane
segments [16, 17, 21, 29], consequently, it is not surprising
that many compounds bind with high affinity to all these
three receptor subtypes.
Initial studies on 5-HT2 receptor signalling showed that these
receptors activate the heterotrimeric G proteins that contain
the q subunit, thereby stimulating phospholipase C and
leading to phosphatidyl inositol hydrolysis [35]. These
receptors also stimulate phospholipase A2 and the NO/cyclic
GMP (cGMP) pathway. However, some differences in the
signal transduction characteristics of these receptors have
been reported [40, 41]. Studies focusing on the regulation of
the 5-HT2 receptor family have also indicated that 5-HT2
receptors are non-classically regulated. Indeed, 5-HT2
receptor responsiveness is not only decreased following
chronic agonist exposure but also, paradoxically, after
chronic treatment with antagonists such as antipsychotic
compounds [37].
5-HT2A RECEPTORS
The 5-HT2A receptor (formerly called “5-HT2”,
“serotonin 2” or “S2” receptors and thought to correspond to
the D receptors) is comprised of 471 amino acids in rats,
Table 1. Nomenclature and Classification of the Serotonin Receptor Subtypes
Receptor Agonist Antaganist
Seven-transmembrane-spanning, G-protein-coupled receptors
Negatively coupled to adenylate cyclase (Gi/o))
5-HT1A 8-OH- DPAT WAY-100635
5-HT1B CP 93129 GR127935
5-HT1D PNU 109291 BRL-15572
5-HT1E - -
5-HT1F LY-334370 -
Positively coupled to adenylate cyclase (Gs)
5-HT4 RS67333, SB205149 RS39604, SB-207266
5-HT6 - RO630563, SB-271046
5-HT7 - SB-258719, SB-269970
Coupled to phospholipase C (Gq)
5-HT2A DOI
5-HT2B BW-723C86 RS-127445, SB-215505
5-HT2C RO-600175, SB-206553 (inverse agonist) SB-242084, SB-243213
Unknowing coupling
5-HT5A - -
5-HT5B - -
Ligand-gated ion channel/receptor
5-HT3A SR 57227 Granisetron, Ondansetron
5-HT3B - -
5-HT3C - -
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mice and humans and it is heterogeneously distributed in the
mammalian brain [16, 17, 42]. It is abundantly present in the
telencephalon (olfactory system, cerebral cortex, basal
forebrain, neostriatum, hippocampus, amygdala). The 5-
HT2A receptors occur in the diencephalon (dorsal thalamus,
hypothalamus), the mesencephalon (superior collicolus,
substantia nigra reticulata), the methencephalon
(pedunculopontine nucleus, and the latero dorsal tegmental
nucleus) and the myelencephalon (spinal cord neurons and
sympathetic and sensory neurons). The match between
mRNA and protein distribution suggests a predominant
somato-dendritic localisation supported also by the evidence
that the 5-HT2A receptor densities are not diminished by
specific lesion of the serotonergic system [20]. The 5-HT2A
label was detected in the medial prefrontal cortex in some
large- and medium-sized GABAergic interneurons [43-45] in
almost all pyramidal cells [46] and on dopaminergic nerve
terminals [47]. Surprisingly, these studies also revealed a
prominent intracellular localisation of the 5-HT2A receptors
without any enrichment at the plasma membrane level [48].
The role of the intracellular pool remains to be elucidated.
The 5-HT2A receptors within the prefrontal cortex have been
implicated in the pathogenesis and treatment of schizo-
phrenia. Indeed, post-mortem studies have revealed a change
in 5-HT2A receptor density within the prefrontal cortex of
subjects with schizophrenia [49]. Moreover, these receptors
are targets for a large number of non-classical anti-psychotic
drugs. Changes in 5-HT2A receptor density and activity
induced by these compounds likely account for their
therapeutic action in schizophrenia and other pathologies. In
the ventral tegmental area (VTA), 5-HT2A receptors are
present on GABAergic cells, but they are also expressed in
rat and human VTA and substantia nigra pars compacta
(SNc) dopaminergic neurons [50, 51] providing a potential
anatomical basis for the modulation of DA neurons in the
VTA either directly, by 5-HT2A receptors localized on DA
cells, or indirectly, through localisation on non–DA
(GABAergic) neurons [51, 52]. In the basal forebrain, 5-
HT2A receptors are presumably localised on cholinergic cells
of the lateral septal nucleus and the basal nucleus of Meynert
[53]. The reduction of 5-HT2A receptors in the brains of
patients suffering from Alzheimer’s disease may be a
consequence of the degeneration of cholinergic neurons [53].
Dense labelling of 5-HT2A receptor immuno-reactivity was
found in the pedunculopontine and latero-dorsal tegmental
nuclei. In these nuclei, 5-HT2A receptors seem to occur only
on local GABAergic interneurons and not on cholinergic
cells [54, 55].
Table 2. The Anatomical Distribution of Serotonin Receptors in the CNS
Receptor subtype Receptor Distribution
5-HT1A Raphe nucli (somatodendritic autoreceptors), limbic system (amygdala, hippocampus, septum).
5-HT1B Basal ganglia  (terminal autoreceptors).
5-HT1D Raphe nuclei.
5-HT1E Caudate putamen, entorhinal cortex, parietal cortex, thalamus, hypothalamus.
5-HT1F Dorsal raphe, hippocampus, cortex, striatum, thalamus, hypothalamus.
5-HT2A Cortex, basal ganglia,  spinal cord.
5-HT2B Cerebellum, lateral septum, hypothalamus.
5-HT2C Dorsal raphe, choroid plexus, medulla, pons, striatum, nucleus accumbens, hippocampus, hypothalamus, ventrotegmental area,
substantia nigra, spinal cord.
5-HT3A/3B/3C Caudate putamen, hippocampus, entorhinal cortex, frontal cortex, cingulate cortex, and dorsal horn ganglia.
5-HT4 Striatum, brainstem, thalamus, hippocampus, substantia nigra.
5-HT5A/5B Hippocampus, cortex, cerebellum, habenula, spinal cord.
5-HT6 Caudate putamen, olfactory tubercle, nucleus accumbens, cortex, hippocampus.
5-HT7 Hippocampus, hypothalamus, thalamus, raphe nuclei.
Table 3. Comparison of 5-HT2A, 5-HT2B, and 5-HT2C
Receptor Signal transduction Receptor Distribution Splice Variants
5-HT2A PLC, c-fos, ion flux, PKC activation Cortex > basal ganglia > hippocampus None identified yet
5-HT2B Ras activation, Ca2+ flux Small amounts in various brain areas None identified yet
5-HT2C PLC, PLA2, PLD Choroid plexus > hippocampus > striatum Yes
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5-HT2B RECEPTORS
In contrast to the other 5-HT2 receptors the 5-HT2B
subtype is expressed principally in the periphery and only
sparsely in the CNS [56-58]. Loric and colleagues [59]
isolated the mouse 5-HT2B (formerly 5-HT2F) receptor from a
brain cDNA library and detected transcripts in the mouse
intestine, heart, kidney and brain, but not in the liver or
spleen. The mRNA of the 5-HT2B receptor is present only in
very low concentrations in mouse [59-61] and human brain
[61]. The human 5-HT2B receptor is made up of 481 amino
acids and is relatively homologous with the other 5-HT2
receptors [60]. Using more sensitive techniques, several
groups have also shown the presence of both 5-HT2B
receptor mRNA and protein [62] in the rat brain, more
specifically in the cerebellum, cerebral cortex, hippocampus
and amygdala. At present, little is known about the function
of the 5-HT2B receptor as result of the lack of selective
ligands at these sites. However, it seems that the 5-HT2B
receptor plays an important role during embryonic
development of various apparatuses [63] including the CNS
[64].
5-HT2C RECEPTORS
The 5-HT2C receptor has received less attention in
psychopharmacology compared to the 5-HT2A sites. This
may relate to the inadequacy of techniques to determine the
receptor in tissue samples. However, evidence from a variety
of sources has involved this receptor in several important
physiological and psychological processes including motor
function, anxiety, ingestive behaviour and in brain
development [33, 38, 65-67]. 5-HT2C receptor-deficient mice
are overweight as a result of abnormal control of feeding
behaviour [68, 69], thus this receptor could play a role in the
serotonergic control of appetite. Mutant animals are also
prone to spontaneous death from seizures, suggesting that
receptors of this type mediate tonic inhibition of neuronal
network excitability. Direct activation of the 5-HT2C
receptors by agonists in normal rats decreases their food
intake, and central 5-HT systems probably directly activate
pro-opiomelanocortin (POMC) neurons via the 5-HT2C
receptors [70-73]. The 5-HT2C receptor knockout mice are
also more wakeful, and show several abnormalities in rapid
eye movement (REM) sleep expression and enhanced
response to sleep deprivation compared with wild-type
control mice. These findings suggest that the 5-HT2C recep-
tors may mediate several effects on sleep that have been
ascribed to 5-HT [27]. Furthermore, some interesting
pharmacogenetic observations have focused on the potential
importance of this receptor for the development of novel
antipsychotic, antidepressant, and antiepileptic drugs [31, 32,
65].
5-HT2C RECEPTOR STRUCTURE, SIGNAL TRANS-
DUCTION AND PHARMACOLOGY
The 5-HT2C receptor gene is unique among the members
of the 5-HT receptors family by virtue of its genomic
organization. The human 5-HT2C receptor gene has been
mapped to X-chromosome band q24 [74] and shown to
contain six exons and five introns. The coding region of the
gene, unlike many other genes for GPCRs, is interrupted by
three introns, and the positions of the intron/exon junctions
are conserved between the human and the rodent genes [75].
The gene product is a protein of 460 amino acids, heavily
glycosylated and migrating as a 60-kDa protein [76]. The 5-
HT2C receptor is a member of the GPCR superfamily with 7-
transmembrane spanning domains and three intracellular
loops connecting them (Fig. 2). Among the intracellular
loops the second one that connects transmembrane helices 3
and 4 has an important role in G protein coupling [77].
However, full G protein activation has been shown to require
both the second (i2) and the third intracellular loops (i3),
suggesting they act in synergy [78]. The 5-HT2C receptor is
the only known GPCRs whose mRNA undergoes post-
trascriptional editing to yield different isoforms [79]. A
naturally occurring variation in i2 was shown as result of
adenine deaminase editing of the receptor mRNA. This leads
to substitution of amino acids in the i2 of the receptor at
position 156, 158 and 160 (Fig. 2). Although RNA editing
produces at least 14 functional isoforms (and potentially
many more) of the receptor, these isoforms are associated
with a variation in the efficacy of their interaction with G
protein [80-82]. In this regard, it was recently reported that
the depletion of 5-HT increases expression of 5-HT2C mRNA
isoforms encoding receptors with higher sensitivity to 5-HT.
This evidence suggests that this editing acts as a fine-tuning
mechanism that adjusts receptor function to changes in
synaptic activity, to maintain their normal response proper-
ties to agonist stimulation [83]. Interestingly, alteration of
the 5-HT2C pre-mRNA editing has been implied in several
psychiatric disorders. Indeed, distinct site-specific alteration
of this editing has been found in the prefrontal cortex of
patients with schizophrenia and major depression. Hitherto,
the most complex alteration in 5-HT2C pre-mRNA editing
was retrieved in brains of depressed suicide victims. In these
brains, 5-HT2C receptor isoforms with reduced function were
expressed at significantly increased levels, suggesting that
the regulation of editing by synaptic 5-HT is defective [84].
Decreased agonist binding affinity has also been linked to
RNA editing, however antagonist binding remained
unaltered [85].
A splice variant of the 5-HT2C receptor has been identi-
fied, but due to a truncated C terminus, displayed neither G-
protein coupling nor ligand binding [81]. Recently, it has
been reported that the 5-HT2C receptors, like other GPCRs,
exist as constitutive homodimers on the plasma membrane of
living cells [86]. The same authors have subsequently shown
that one 5-HT2C dimer binds two molecules of ligand and
one G-protein [87]. Whilst it has been clearly shown that
homodimerization of GPCRs regulates ligand binding,
second messanger activation, and receptor trafficking [88],
the functional significance of 5-HT2C receptor dimerization,
remains unknown. If this phenomenon plays a role in
regulating the function of the 5-HT2C receptor, it could have
important implications for the development of novel
serotonergic therapeutic agents.
The 5-HT2C receptors share extensive sequence similari-
ties with the 5-HT2A receptors. Thus, it is not surprising that
they have very similar pharmacological profiles and that they
activate the same signalling pathways. However, some
differences in signal transduction characteristics of both
receptors have been reported. Agonist binding to the 5-HT2C
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receptor activates phospholipase C (PLC) via G protein
(Gq/11) (Fig. 3 ). Thus phospholipase C catalyses the
hydrolysis of phosphadytilinositol-4,5-biphosphate to
inositol 1,4,5-triphosphate (IP3) and diacylglycerol. IP3,
acting as a second messenger, diffuses through the cell
cytoplasm and stimulates the release of Ca
2+
 sequestered in
the endoplasmatic reticulum which in turn activates
numerous cellular processes through the intermediacy of
calmodulin and its homologues. The diacylglycerol remains
associated with the plasma membrane where it activates
protein kinase C to phosphorylate and thereby modulates the
activities of a number of cellular proteins [89-92]. However,
other different signalling pathways for the 5-HT2C receptor
subtype have been shown (Fig. 3). Indeed, some agonists
binding to the 5-HT2C receptor can instead activate phos-
pholipase A2 (PLA2) leading to the release of arachidonic
acid (AA) [41]. Furthermore, 5-HT2C receptors can also
activate phospholipase D (PLD), involving G13 and free
G subunits [93], and the mitogen-activated protein kinase,
extracellular signal-regulated kinase (ERK) 1 and 2 [94].
Interestingly, it was shown that coupling of 5-HT2C receptors
to G13 and Gq/11 can be differentially stimulated by certain
agonists; ergots preferentially Gq/11, whereas 5-HT and (S)-2-
(chloro-5-flouro-indo-l-yl)-l-methylethylamine fumarate
(RO 60-0175), a selective 5-HT2C receptor agonist, are
equally efficacious towards both pathways. Differential G-
protein coupling appeared to depend on receptor reserve [95]
and was regulated by RNA editing [80, 96]. The latter may
alter the ability of LSD to stimulate IP3 formation. These
observations suggested that it may be possible to develop
agonists which preferentially act in specific tissues via a
specific signalling pathway. Amongst the 5-HT2 receptor
family, 5-HT2C appears more prone to exhibit intrinsic
constitutive activity. In this regard, studies have
demonstrated the considerable ability of the native 5-HT2C
receptor to spontaneously activate intracellular signalling
pathways, including PLC and PLA2, in the absence of
agonist stimulation [97-100]. This quite peculiar 5-HT2C
receptor characteristic occurs not only in recombinant cells
but also in natural tissues and it seems to play an important
role in the tonic control of the central dopaminergic function
[101, 102]. The occurrence of constitutive receptor activity
allows the detection of compounds that can block this
activity, the so-called inverse agonists [97]. Inverse agonists
may show differential pharmacological and clinical effects as
compared to mere antagonists and bring up important
therapeutic perspectives [103]. For instance, several atypical
antipsychotic drugs display inverse agonist activity at
constitutive 5-HT2C receptors [102, 104]. Furthermore, it has
been shown that the typical antipsychotic haloperidol despite
its absence of affinity for the 5-HT2C receptors increases the
level of their constitutive activity [102], and this, most likely,
through an action at the level of common pathways [105].
Recently, it has been shown that the affinity and efficacy of
5-HT for 5-HT2C receptors can be potentiated also via
allosteric modulation by amphipathic lipid metabolites [106].
Im and colleagues hypothesized that this modulation could
also occur in nature and represent another route of
constitutive activation of the 5-HT2C receptors [106].
In contrast to most other receptors 5-HT2C is not
classically regulated. Indeed, 5-HT2C receptors appear not
only to decrease their responsiveness upon chronic agonist
stimulation, but also and paradoxically after chronic
treatment with antagonists [107, 108]. This mechanism
appears to be related to an internalisation process that
removes activated cell surface receptors from the plasma
membrane involving a phosphorylation step and possible
degradation in lysosomes [37]. As a large number of psycho-
tropic drugs, including atypical antipsychotics, antidepres-
sants, and anxiolitics, can all induce down-regulation of 5-
HT2C receptors, it has been suggested that this alteration
plays a role in the therapeutic action of these drugs [35, 37].
5-HT2C RECEPTOR DISTRIBUTION AND CIR-
CUITRY IN CNS
Pazos and colleagues first identified the 5-HT2C receptors
by radioligand binding 
3
H-5-HT and 
3
H-mesulergine in the
Fig. (2). Helical net representing the amino acid sequence of the unedited 5-HT2C receptor. Residues in the second intracellular loop where
the pre-mRNA editing occurs are not coloured and are highlighted by a thick dark circle.
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pig choroid plexus and initially called it 5-HT1C because of
its high affinity for tritiated 5-HT [109]. However, once the
receptor was cloned and more information about its
characteristics became available, a shift to the 5-HT2
receptor family and reclassification as 5-HT2C became
accepted. Later studies using autoriadiography with 
3
H-
mesulergine have confirmed a conspicuously high binding
site density in the choroid plexus in all mammalian species,
including subhuman and human primates. High density is
also found in the SNr, globus pallidus and ventro medial
thalamus with low amounts detected in many other brain
areas [110-112]. A widespread distribution of 5-HT2C
receptor mRNA has been demonstrated in rat, monkey and
human brains using in situ hybridization techniques [113-
116]. 5-HT2C receptors are more abundant and more widely
expressed in the brain than 5-HT2A receptors, although there
are several areas where both receptors coexist [117]. As was
found for 5-HT2C binding sites, the choroid plexus also
contained the highest amounts of 5-HT2C receptor mRNA
and protein, mainly associated with choroid epithelial cells.
Consequently, a role for these receptors in the regulation of
the volume and composition of the cerebral fluid has been
hypothesized [118]. High levels of both 5-HT2C protein and
mRNA have been found in several cortical areas, in the
hippocampus, striatum, septal nuclei, thalamic nuclei,
midbrain nuclei, brain stem nuclei and the spinal cord [113,
117, 119]. Messenger RNA has been found in the locus
coeruleus, SNc and VTA, basal nucleus of Meynert and
lateral dorsal tegmental nucleus, suggesting a role for 5-HT2C
receptors in the serotonergic regulation of chatechola-
minergic and cholinergic systems. A number of studies have
concentrated on the localization and potential role of 5-HT2C
receptors in the basal ganglia. Studied concomitantly, 5-
HT2C and 5-HT2A receptor mRNA was found to be co-
localized with substance P and dynorphin in striato-nigral
projections and with enkephalin in striato-pallidal
projections. However, 5-HT2A and 5-HT2C receptor mRNA is
differentially localized with regard to the scattered islands of
strongly dynorphin mRNA positive cells; 5-HT2C receptor
mRNA occurs more in the surroundings areas, as compered
to 5-HT2A receptor mRNA [120]. Within the neostriatum, 5-
HT2C receptors mRNA labeled neurons are more numerous
in the ventral and ventro-lateral than in the dorsal caudate-
putamen, where labeled neurons are restricted to isolated
clusters. In the striatal target areas, dense labeling is found in
the entopeduncular nucleus (internal pallidum) while no
mRNA is found in the globus pallidus (external pallidum),
an area where 5-HT2C receptor binding sites have been
detected. 5-HT2C receptor mRNA also occurs in the
subthalamus, where the receptors could be involved in the
oral dyskinesia that is induced by drugs with 5-HT2C agonist
action [121]. In the substantia nigra and in the VTA, 5-HT2C
receptor expression is confined to GABAergic neurons
making direct synaptic contact with dopaminergic cell
bodies. Other immunoistochemical and electrophysiological
studies [7, 122-124] have corroborated this piece of evidence
suggesting an indirect control of dopaminergic transmission
via 5-HT2C receptors. Dense 5-HT2C receptor labeling is
found in about half of the neuronal population of the middle
and caudal SNc and SNr. 5-HT2C receptors could thus
selectively affect discrete neuronal population in the basal
ganglia and mesolimbic system [121, 124]. 5-HT2C receptor
mRNA is expressed also in the midbrain raphe nuclei and
surroundings areas [113, 125]. Similar to other brain areas,
experimental findings to date seem to suggest that in the
raphe nuclei there is a good concordance between the
distribution of 5-HT2C receptors mRNA, 5-HT2C receptors
immunoreactivity and 5-HT2C receptors binding sites [110,
113, 117, 125, 126], suggesting that 5-HT2C receptors are
located at the level of the cell body and/or dendrites.
Furthermore, a recent in situ hybridization study has shown
that the 5-HT2C receptors mRNA is not expressed by
serotonergic cells but, in contrast, it was found in the
majority of GABAergic neurons located within the DRN and
MRN [127] showing a similar pattern to the SNc and VTA
[121, 124]. In view of these anatomical data and from in
vitro electrophysiology evidence [128], the blockade of the
5-HT2C receptors on DRN GABAergic interneurons might be
used to decrease the GABAergic tone and indirectly increase
the firing of 5-HT cells an action belonging to many
antidepressant drugs.
In the spinal cord, 5-HT2C receptor mRNA is expressed at
high levels in most of the grey matter [129]. The evidence
that 5-HT2C receptors activation induces penile erection in
rats is consistent with the presence of these receptors on
neurons of the lumbo-sacral spinal cord involved in erection
and ejaculation [130].
5-HT2C AND CENTRAL DOPAMINERGIC FUNC-
TION
Among the multiple classes of 5-HT receptors described
in the central nervous system [16, 17], much attention has
been devoted to the role of the 5-HT2 receptor family in the
control of central DA activity, because of the moderate to
dense localization of both transcript and protein for the 5-
HT2A and 5-HT2C receptors in SN and VTA as well as DA
terminal regions of the rat forebrain [51, 52, 117, 131].
Fig. (3). Schematic drawing showing the different signal transduc-
tion pathways of the 5-HT2C receptor. Abbreviations: PLC,
phospholipase C; PLA2, phospholipase A2, PLD, phospholipase D;
?, unknown signal transducing molecule.
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The involvement of 5-HT2C receptor subtypes in the
control of mesocorticolimbic and nigrostriatal DA neuron
activity is now well established [65, 102, 124, 132-140], and
evidence has been provided that they exert both tonic and
phasic modulation of DA function [101, 135-143]. More
than 10 years ago, we suggested that 5-HT could exert an
inhibitory action on DA neurons in the VTA by acting
through 5-HT2 receptors [144]. In fact, we showed for the
first time that the firing rate of DA neurons in the VTA was
reduced by mCPP and trifluoromethylphenylpiperazine
(TFMPP), two mixed 5-HT2A/2B/2C receptor agonists [29],
whereas these neurons were stimulated by mesulergine
[144]. However, these data did not allow us to distinguish
the relative contribution of each 5-HT2 receptor subtype in
the control of central DA function. Subsequently, our studies
clearly indicated a selective involvement of 5-HT2C receptors
on the basis of the evidence that the inhibitory effect of the
mixed 5-HT2 receptor agonists mCPP and 6-chloro-2-(1-
piperazinyl)piperazine (MK 212) on the activity of VTA
DA-containing neurons and on accumbal DA release was
completely prevented by 6-chloro-5-methyl-1-[2-(2-
methylpyridiyl-3-oxy)-pyrid-5-yl carbamoyl] indoline (SB
242084), a selective 5-HT2C receptor antagonist [139].
Moreover, SB 242084 blocked the inhibitory action of the
selective 5-HT2C receptor agonist RO 60-0175 [138].
Another series of studies has shown that 5-methyl-1-(3-
pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f ]indole)
(SB 206553), a selective 5-HT2C/2B receptor inverse agonist
[101, 145], increases the basal firing rate and the bursting
activity of VTA and SNc DA neurons [136] and enhances
DA release in the rat nucleus accumbens, striatum and
prefrontal cortex [101, 134, 136, 137, 140]. In addition to a
local effect on DA cell bodies, the 5-HT2C receptors located
on the nerve terminal regions seem to play a role in the
regulation of DA release. Indeed, local administration of SB
206553 increased DA efflux in the striatum and this effect
was attenuated by systemic administration of mCPP [140].
Consistent with these findings, 6-chloro-5-methyl-l-[2-(2-
methylpyridiyl-3-oxy)-pyrid-5-yl carbomoyl] indoline (SB
242084), a powerful and selective 5-HT2C receptor
antagonist [145], selectively enhanced the mesocorticolimbic
DA function, while RO 60-0175 and MK 212, two 5-HT2C
receptor agonists, reduced it [101, 146, 147]. Recently, it has
been demonstrated that the constitutive activity of the 5-
HT2C receptors participates in the tonic inhibitory control
that they exert on DA release in the rat striatum and nucleus
accumbens in vivo [101]. Moreover, SB 242084 was found
to potentiate phencyclidine-induced increase in accumbal
DA release [141], and stress-stimulated DA outflow in the
rat prefrontal cortex [142], while stimulation of 5-HT2C
receptors by RO 60-0175 in the VTA suppressed it [142],
suggesting a role for these receptors on evoked DA release
also. Interestingly, some of our data show also that the
nigrostriatal DA system is less sensitive to the pharma-
cological manipulation of the 5-HT2C receptors. Indeed, there
is evidence that 5-HT2C receptor agonists such as mCPP, MK
212, and RO 60-0175 do not significantly affect the activity
of SNc DA neurons and the in vivo DA release in the
striatum [139, 146]. On the other hand, the selective 5-
HT2B/2C inverse agonist SB 206553 caused only a slight
increase in the basal activity of DA neurons in the SNc and
in striatal DA release [139]. Consistently, a study carried out
in our laboratory has shown that mCPP excites non-DA
(presumably GABA-containing) neurons both in the SNr and
the VTA by activating 5-HT2C receptors [124]. Despite the
evidence that all non-DA neurons in the VTA were being,
equally, excited by mCPP, different effects were observed in
the SNr. Thus, mCPP caused a marked excitation of
presumed GABAergic SNr projection neurons but did not
modify the SNr interneurons firing discharge [124]. It is
tempting to speculate that this differential response to mCPP
might be the basis of the preferential inhibitory effect of 5-
HT2C agonists on the mesocorticolimbic versus the
nigrostriatal DA function. Recently, it has been hypothesized
that 5-HT2C receptor activation may also inhibit DA neurons
via a long feedback loop involving glutamatergic pyramidal
cells located in the prefrontal cortex [148]. In fact, it has
been shown that approximately 60% of VTA mesoprefrontal
projections are GABAergic [149] and the activation of this
pathway could therefore play an important role in modula-
ting excitatory outputs to sub-cortical structures [148].
5-HT2C RECPTORS AND DEPRESSION
A large body of evidence suggests that the serotonergic
system is impaired in depression. Most neurochemical and
neuroendocrine studies of patients with depression are
consistent with the existence of a serotonergic deficit.
Consistently, selective serotonin re-uptake inhibitors (SSRIs)
and monoamino oxidase inhibitors (MAOIs) are clinically
effective antidepressants and both increase extraneuronal 5-
HT acutely. When mirtazapine (Remeron), a noradrenergic
and specific serotonergic antidepressant (NaSSA) that
showed high affinity for the human 5-HT2C receptors, came
on to the market attention was drawn to the possible
importance of 5-HT2C blocking activity for the treatment of
symptoms of depression [33, 150, 151]. This hypothesis is
consistent with the evidence that some antidepressant drugs
display prominent 5-HT2C receptor binding, e.g. tricyclics
(amitriptyline, imipramine), mianserin, nefazodone, opipra-
mole, trazodone [67, 152, 153] and fluoxetine [148, 154].
Based on those findings, Di Matteo and colleagues [155]
have carried out experiments showing that acute
administration of amitriptyline and mianserin enhances DA
release in the rat nucleus accumbens by blocking 5-HT2C
receptor subtypes. However, these drugs have multiple
receptor and transporter interactions and it is difficult to
asses what the real contribution of the 5-HT2C receptor
blockade is to the total clinical activity of the drugs.
The possible involvement of the 5-HT2C receptor in the
pathogenesis of depressive disorders and in the mode of
action of antidepressants is further substantiated by several
other observations. The chronic mild stress procedure, which
is capable of inducing a depression-like state in animals, was
shown to enhance 5-HT2C receptor mediated function, as
measured in vivo by mCPP induced penile erections.
Conversely, two different antidepressant treatments (72-h
REM sleep deprivation and 10-day administration of
moclobemide, a reversible type A MAOI) resulted in a
reduction of this 5-HT2C receptor-mediated function [156],
supporting the hypothesis that 5-HT2C receptor may be
altered, and presumably may exist in a dysregulated
(hypersensitive) state in depressive illness. The adaptive
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processes resulting from chronic antidepressant treatment
(i.e., desensitization and/or downregulation of 5-HT2C
receptors) may normalize this dysregulated state [157]. In
this respect, it is interesting to note that chronic treatment
with 5-HT2 agonists or antagonists resulted in a paradoxical
down-regulation at the 5-HT2A and 5-HT2C receptors [157-
160] and it seems that the down-regulation state obtained
after chronic exposure to mianserin in isolated systems as
well as in cell cultures, is a direct receptor-mediated
mechanism of this drug at these receptors [160]. Therefore,
the down-regulating capacity of 5-HT2C agonists and
antagonists may play a particularly important role in treating
the supersensitivity of the 5-HT2C receptor system resulting
from a depressive state [67, 157]. Behavioural effects of
antidepressant drugs also support the role of this receptor in
the pathogenesis of depression: in the modified rat forced
swim test three selective 5-HT2C receptor agonists, WAY
161503, RO 60-0175 and RO 60-0332, were demonstrated to
have antidepressant activity, similar to fluoxetine [161]. On
the other and, interactions between several doses of RO 60-
0175 and antidepressant drugs, such as tricyclics and SSRIs
were found effective in the mouse forced swimming test
[162], and antagonism at 5-HT2C receptors significantly
enhanced the anti-immobility effects of imipramine in the
same mouse test [163]. It was also demonstrated that a 5-
HT2C receptors mutation may contribute to the pathogenesis
of major depression and bipolar disorder [164]. Intriguing
evidence also shows an alteration of 5-HT2C pre-mRNA
editing in the brains of major depressed and depressed
suicide victims especially in the prefrontal cortex, a brain
area expressing a large number of differently edited 5-HT2C
mRNA isoforms [84]. Since these changes were opposite to
those detected in mice chronically treated with fluoxetine
[83], the therapeutic effect of SSRIs could be in part
explained with the reversing of 5-HT2C receptor mRNA
editing abnormalities.
Several lines of evidence indicate that 5-HT2C receptor
antagonists maybe used to augment the therapeutic efficacy
of SSRIs. [165, 166]. Thus, agomelatine, the first melato-
nergic antidepressant with 5-HT2C antagonist properties, was
observed to produce a robust augmentation of citalopram-,
fluoxetine-, and sertraline-induced elevations of hippo-
campal extracellular 5-HT levels [165, 166]. The
potentiation of SSRI-induced increases in hippocampal 5-HT
levels was reproduced by the 5-HT2C receptor-selective
antagonists SB 242084 and RS 102221, but not by the 5-
HT2A receptor-selective antagonist MDL 100,907. Although
5-HT2C receptor antagonists potentiated the actions of SSRIs,
they had no effect on extracellular 5-HT levels or tail
suspension responses when administered alone. These results
corresponded well with independent findings using a line of
5-HT2C receptor null mutant mice [165]. Although this
mutation did not affect baseline extracellular 5-HT levels or
tail suspension test (TST) behaviour, it enhanced fluoxetine-
induced effects on 5-HT levels and immobility in the TST.
Since the 5-HT2C receptors have recently been found to
be expressed specifically on GABAergic neurons of the
anterior raphe nuclei [127], it is conceivable that blockade of
these receptors could disinhibit serotonergic neurons. This
hypothesis is strengthened by the evidence that stimulation
of the 5-HT2 receptors by serotonin activates local GABA
inhibitory inputs to 5-HT-containg neurons in the dorsal
raphe nucleus, an effect which is partly mediated by 5-HT2C
receptor subtypes [128]. Whether 5-HT/DA interaction is
involved in the mechanism of augmentation of the SSRI
antidepressant effect exerted by the 5-HT2C receptor
antagonists is presently unclear, and it remains to be
determined. Nevertheless, it is tempting to speculate that a
blockade of 5-HT2C receptors would increase the
serotonergic tone to VTA DA neurons, which would be
excited by the excess of 5-HT acting on free 5-HT2A
receptors. Thus, the pharmacological blockade of 5-HT2C
receptors would favour an unbalanced excitatory effect of 5-
HT acting through 5-HT2A receptors whose stimulation is
known to cause a direct depolarization of DA-containing
neurons in the VTA [128]. However, this hypothesis needs
experimental demonstration to be confirmed. Another
important contribution to the research regarding 5-HT/DA
interaction and the effects of antidepressant drugs comes
from the data obtained in our laboratory showing that acute
administration of fluoxetine causes a dose-dependent
inhibition of the firing rate of VTA DA neurons, but it does
not affect the activity of DA cells in the SNc [167]. A similar
effect, though less pronounced, has been observed with
citalopram [167]. Furthermore, mesulergine, an unselective
5-HT2C receptor antagonist [21], as well as the destruction of
5-HT neurons by the neurotoxin 5,7-dihydroxytryptamine
(5,7-D-HT), prevented the fluoxetine-induced inhibition of
VTA DA cells [167]. These results indicate that fluoxetine
inhibits the mesolimbic DA pathway by enhancing the
extracellular level of 5-HT, which would act through 5-HT2C
receptors [167]. This study also demonstrated that
fluoxetine-induced inhibition of DA neurons in the VTA was
no longer observed after chronic treatment (21 days) with
this drug. Interestingly, mCPP inhibited the firing activity of
VTA DA neurons in control animals but not in those
chronically treated with fluoxetine [167]. The authors
suggested that 5-HT2C receptors might be downregulated
after repeated fluoxetine administration. Consistent with this
hypothesis is the evidence that chronic treatment with
sertraline and other SSRIss, such as sertraline, fluoxetine,
fluvoxamine and citalopram, induces tolerance to the
hypolocomotor effect of mCPP [168-171]. This hyposen-
sitivity of 5-HT2C receptors might be a key step for the
achievement of an antidepressant effect. Indeed, it is possible
to argue that the acute inhibitory effect of fluoxetine on the
mesolimbic DA system would mask its clinical efficacy in
the early stage of treatment. This masking effect would
disappear when the hyposensitivity of 5-HT2C receptors
occurs. A series of studies carried out in our laboratory have
shown that acute administration of SSRIs such as paroxetine,
sertraline, and fluvoxamine causes a slight but significant
decrease in the basal firing rate of VTA DA neurons [172].
Therefore, it is conceivable that, similar to fluoxetine, these
three SSRIs could reduce mesocorticolimbic DA transmis-
sion by activating 5-HT2C receptors.
5-HT2C RECPTORS AND SCHIZOPHRENIA
The original observation of the structural similarity
between 5-HT and the hallucinogic drug lysergic acid
diethylamide (LSD) led to the hypothesis that schizophrenia
may be associated with a dysfunction of the 5-HT system
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[173, 174]. However, the initial excitement about a 5-HT-
related hypothesis of schizophrenia was diminished by the
recognition that LSD-induced psychosis differed in several
ways from the symptoms seen in schizophrenia [175].
Nevertheless, renewed interest in 5-HT as a player in the
pathophysiology of these disorders was brought about when
it was shown that the atypical antipsychotic clozapine had
high affinity to 5-HT2 receptors [176] and displayed a
superior therapeutic effect as compared to classical antipsy-
chotic in treatment-resistant schizophrenia [177].
Thus, it was hypothesised that the action of atypical
antipsychotic drugs (APDs) depends on their interaction with
central 5-HT2A or 5-HT2C receptor subtypes, more than with
D2 receptors [34, 178-181]. In fact, by examining in vitro
receptor binding data, Meltzer and collaborators [34] found
that typical and atypical APDs could be distinguished on the
basis of their 5-HT2 to D2 receptor binding ratios.
Early clinical studies indicated that the selective 5-
HT2A/2C receptor antagonist ritanserin [182, 183] can
ameliorate negative symptoms as well as attenuate exciting
extrapiramidal side effects (EPS) in schizophrenics treated
with classical APDs [184, 185]. To date, it is generally
accepted that the mechanism of action of atypical APDs is
based on their ability to achieve a balanced 5-HT2 to D2
receptor antagonistic action and not on their absolute affinity
for these receptors per se. Clearly, such hypotheses have
pushed for the development of novel APDs with combined
antiserotonergic and antidopaminergic properties. Canton
and colleagues [186], initially showed the high affinity of
clozapine and risperidone also for 5-HT2C sites in the rat
choroid plexus. These findings were subsequently confirmed
[187-191] and extended to brain sections [190-191], and in
transiently expressed 5-HT2C receptors [35, 181]. Antago-
nism at 5-HT2C receptors by several antipsychotics was also
observed in vivo. Indeed, clozapine produces an increase in
extracellular levels of DA in the nucleus accumbens [192,
193], reverses the inhibition of accumbal DA release induced
by the 5-HT2C agonist RO 60-0175 [192] and blocks the
hypolocomotion induced by the 5-HT2C agonist mCPP [194].
It is worth noting that clozapine, like several atypical
APDs, behaves as a 5-HT2C inverse agonist in heterologus
expression systems in vitro [195, 102, 104] and in vivo [102].
Thus, the 5-HT2C receptor inverse agonist might underlie the
unique clinical properties of atypical APDs [102, 195]. The
modification of 5-HT2C receptors constitutive activity may
also participate in the effects of the typical APD haloperidol.
Indeed, it has been reported that the increase in striatal DA
release induced by haloperidol is dramatically potentiated by
the 5-HT2C inverse agonist SB 206553 [102]. Therefore,
bearing in mind that haloperidol does not bind to 5-HT2C
receptors it was suggested that it could act at the level of the
common effector pathway [102]. A preferential increase of
DA release in the medial prefrontal cortex seems to be a
common mechanism of action of atypical APDs, an effect
which might be relevant for their therapeutic action on the
negative symptoms of schizophrenia [196]. In this respect, it
is important to note that the selective 5-HT2C receptor
antagonist SB 242084 [130] markedly increases DA release
in the frontal cortex of awake rats [134, 147]. Thus, it is
possible to argue that a blockade of 5-HT2C receptors might
contribute to the preferential effect of atypical antipsychotics
on DA release in the prefrontal cortex and mitigate side
effects induced by D2 antagonism.
For the moment, neither a highly selective 5-HT2C
receptor antagonist nor a true mixed 5-HT2A/2C receptor
antagonist has been evaluated in schizophrenia. Behavioural
studies with SB 228537, a selective 5-HT2B/2C receptor
antagonist and using selective 5-HT2A and 5-HT2B receptor
antagonists as controls indicate that 5-HT2C receptor
antagonism can produce a significant reversal of haloperidol-
induced catalepsy [197]. However, not all atypical APDs are
5-HT2C receptor antagonists, for example, risperidone [181].
5-HT2C RECEPTORS AND PARKINSON’S DISEASE
Another interesting application of the data regarding the
functional role of 5-HT2C receptors in the basal ganglia is the
possible use of 5-HT2C receptor antagonists in the treatment
of Parkinson’s disease. The neural mechanisms underlying
the generation of parkinsonian symptoms are thought to
involve reduced activation of the primary motor and
premotor cortex and supplementary motor areas, secondary
to overactivation of the output regions of the basal ganglia,
i.e. SNr and globus pallidus internus (GPi) [198], largely
because of an excessive excitatory drive from the
subthalamic nucleus (STN). Therapy of Parkinson’s disease
consists mainly of amelioration of symptoms with classical
dopaminomimetics [199]. This treatment, however, is
characterized by a declining efficacy and the occurrence of
disabling side-effects [200]. Functional inhibition of GPi or
STN has provided an alternative to lesioning, by deep brain
stimulation associated with modest side-effects [201]. As
already mentioned, 5-HT2C receptors are located in the SNr
and medial segment of the pallidal complex in the rat and
human brain [121, 131], and enhanced 5-HT2C receptor-
mediated transmission within the output regions of the basal
ganglia in parkinsonism appears to contribute to their
overactivity [202]. In addition, 5-HT2C -like receptor binding
is increased in a rat model of parkinsonism [203] and in
human parkinsonian patients [204]. This suggests a
compensatory up-regulation of 5-HT2C receptors as a
consequence of a reduced 5-HT level in output regions of the
basal ganglia, leading to a decreased activity of these nuclei
and an increase in abnormal movements like dyskinesia
[205, 206]. Furthermore, systemic administration of SB
206553 was shown to enhance the action of the anti-
parkinsonian action of the dopamine D1 and D2 agonists in
the 6-hydroxydopamine-lesioned rats [205, 207], suggesting
that the use of a 5-HT2C receptor antagonist in combination
with a dopamine receptor agonist may reduce the reliance
upon dopamine replacement therapies and may thus reduce
the problems associated with long term use of currently
available antiparkinsonian agents [202].
It would, therefore, appear that 5-HT2C receptors play a
significant role in the basal ganglia and that drugs acting on
5-HT2C receptors could have the potential to alleviate the
dyskinesia in the parkinsonian patient, and also the comorbid
depression that often accompanies Parkinson’s disease by
elevating accumbal DA levels [101, 136, 140], thereby
alleviating the anhedonia associated with depression [208].
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5-HT2C RECEPTORS AND DRUG OF ABUSE
Substantial evidence indicates that the mesolimbic
pathway, particularly DA cells innervating accumbal areas,
is implicated in the reward value of both natural and drug
reinforcers, such as, for example, sexual behaviour or
psychostimulants, respectively [209-211]. The fact that drugs
of abuse act through different cellular mechanisms leads to
the possibility that their effect on DA release could be
modulated differentially by each of the 5-HT2 receptor
subtypes. Moreover, it has been reported that the increased
locomotor activity, as well as the accumbal DA release,
elicited by phencyclidine is further enhanced by the blockade
of 5-HT2C receptors [141], while antagonism at 5-HT2A
receptors had opposite effects [212]. A similar picture
emerges when looking at the influence of these receptors on
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-
induced effects on DA neuron activity. Thus, the selective 5-
HT2A antagonist MDL 100,907 significantly reduced the
hyperlocomotion and stimulated DA release produced by
MDMA while the selective 5-HT2C antagonists SB 242084
and SB206553 potentiated it [213-216].
Recently, it was found that SB 206553 administration
potentiates both the enhancement of DA release in the
nucleus accumbens and striatum and the increase in VTA
and SNc DA neuron firing rate induced by morphine [217].
Consistent with this finding, stimulation of central 5-HT2C
receptors has been shown to inhibit morphine-induced
increase in DA release in the nucleus accumbens of freely
moving rats [143]. Blockade of 5-HT2A or 5-HT2C receptors
had opposite effects on cocaine-induced locomotor activity.
Thus, 5-HT2A receptor blockade with M100,907 attenuated
cocaine-induced locomotion, whereas 5-HT2C blockade with
SB 242084 or SB 206553 enhanced cocaine-induced activity
[216, 218-220]. It has been found that RO 60-0175 reduces
cocaine-reinforced behaviour by stimulating 5-HT2C
receptors [221]. Moreover, these authors have also shown
that RO 60-0175 reduces ethanol- and nicotine-induced self-
administration and hyperactivity [222, 223]. Consistent with
these evidences, we recently showed that the selective
activation of 5-HT2C receptors, by RO 60-0175 adminis-
tration, blocks the stimulatory action of nicotine on SNc DA
neuronal activity and the nicotine-induced DA release in the
corpus striatum [224, 225]. The mesolimbic DA system
appeared to be less sensitive to the inhibitory effect of 5-
HT2C receptors activation on nicotine-induced stimulation,
indeed a higher dose of RO 60-0175 was necessary to
prevent the enhancement in VTA DA neuronal firing elicited
by acute nicotine. Furthermore, pretreatment with the 5-HT2C
agonist did not effect nicotine-induced DA release in the
nucleus accumbens [224, 225]. Interestingly, in animals
treated repeatedly with nicotine, pretreatment with RO 60-
0175 reproduced the same pattern of effects on the
enhancement in DA neuronal firing caused by challenge with
nicotine, resulting effective only at a higher dose in
preventing nicotine excitation in the VTA compared to the
SNc. Furthermore, the 5-HT2C receptors agonist counteracted
nicotine-induced DA release both in the striatum and in the
nucleus accumbens in rats chronically treated with this
alkaloid, even if this effect was observed only with the
highest dose of RO 60-0175 [224, 225]. Therefore, we
hypothesized that after repeated nicotine exposure an up-
regulation of 5-HT2C receptors occurs only in the DA
mesolimbic system and the blocking of its hyperfunction by
5-HT2C receptor activation might be a useful approach in
reducing nicotine reward and eventually helping in smoking
cessation.
CONCLUSIONS
Twenty five years of 5-HT2C receptors research have
generated detailed information on the molecular biology,
regional and cellular localization of these receptors.
Furthermore, the 5-HT2C receptor seems to be involved in
the regulation of mood, anxiety, cognitive function, stress,
nociception, sexual functions, feeding, drug abuse, and other
aspects of behaviour. Thus, the 5-HT2C receptors antagonism
appears to be an important feature of antipsychotic and
antidepressants drugs with broad pharmacological profiles,
properties that probably contribute to the treatment of
negative and depressive symptoms, respectively, or to the
mitigation of side-effects. Although several selective agents
for this receptor have been discovered, none have reached
the market for the treatment of CNS disorders to date,
essentially as a result of their limited efficacy. Several
companies are still very active on 5-HT2C receptors research.
Organon has several molecules under clinical evaluation.
Org-12962 stimulates the 5-HT2C receptors and this
compound is now in Phase 2 trials and should at the very
least help to clarify the role of these receptors in depression.
Furthermore, ADP356 (Arena Pharmaceutical) and BVT933
(Biovitrum/GSK), two members of the new generation of 5-
HT2C selective agonists, are currently undergoing clinical
trials for the treatment of obesity, hopefully free of their
predecessors' side effect.
There are also many avenues that remain unexplored, so
there are undoubtedly further advances to be made. In the
next few years, we certainly will see compounds selective
for 5-HT2C receptors making further significant impacts on
the treatment of the major neuropsychiatric disturbances.
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